Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CD96 Biologics Sequence Review Report 2026: T-cell surface protein tactile Similarity and Patent-Risk Signals
8 min read
CD96 Biologics Sequence Review Report 2026: T-cell surface protein tactile Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD96 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGAE Biologics Sequence Review Report 2026: Integrin alpha-E Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGAE Biologics Sequence Review Report 2026: Integrin alpha-E Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAE protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB8 Biologics Sequence Review Report 2026: Integrin beta-8 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGB8 Biologics Sequence Review Report 2026: Integrin beta-8 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB7 Biologics Sequence Review Report 2026: Integrin beta-7 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGB7 Biologics Sequence Review Report 2026: Integrin beta-7 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGA3 Biologics Sequence Review Report 2026: Integrin alpha-3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGA3 Biologics Sequence Review Report 2026: Integrin alpha-3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGA6 Biologics Sequence Review Report 2026: Integrin alpha-6 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGA6 Biologics Sequence Review Report 2026: Integrin alpha-6 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD44 Biologics Sequence Review Report 2026: CD44 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD44 Biologics Sequence Review Report 2026: CD44 antigen Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD44 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD3D Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 delta chain Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD3D Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 delta chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD3D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGAX Biologics Sequence Review Report 2026: Integrin alpha-X Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGAX Biologics Sequence Review Report 2026: Integrin alpha-X Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAX protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGAL Biologics Sequence Review Report 2026: Integrin alpha-L Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGAL Biologics Sequence Review Report 2026: Integrin alpha-L Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAL protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD22 Biologics Sequence Review Report 2026: B-cell receptor CD22 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD22 Biologics Sequence Review Report 2026: B-cell receptor CD22 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD22 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD33 Biologics Sequence Review Report 2026: Myeloid cell surface antigen CD33 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD33 Biologics Sequence Review Report 2026: Myeloid cell surface antigen CD33 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD33 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →